bioihbjkbjnl/mcl2 huggingface dataset:
Effect of Global Postural Reeducation on Low Back Pain Patients With Lower Cross Syndrome
Condition: Low Back Pain, Postural
MeSH terms: Back Pain; Low Back Pain
Study type: Interventional

Summary: 
      This study will be conducted toinvestigate the effect of Global Postural Re-education on low
      back pain patients with Lower cross syndrome
    

Detailed description: 
      Lower cross syndrome is common, with up to 85% of low back pain cases due to long-term
      postural faults (Lower crossed syndrome) and it has a negative result on our society. Global
      Postural Re-education (GPR) is an intervention that is used frequently for chronic low pain
      to improve pain and function. 50 low back pain patients with lower cross syndrome will be
      assigned randomly into 2 groups, Group A will receive a Global Postural Re-education approach
      and consists of 15 treatment sessions of Global Postural Re-education approach, performed
      2times/week for 1 hour including patient education. Each treatment is individualized for
      every patient and for his/her pain-related limitation. Each session includes only 2-3
      postures to increase the standardization of treatment. Group B will receive the conventional
      treatment in form of exercise program of (abdominal and pelvic floor strengthening) and
      (stretching exercise of back and hip flexor muscles) to improve pain and function in chronic
      low back pain patients
    

Intervention name(s): Global postural reeducation
Intervention type(s): Procedure
Intervention description(s): The GPR involves a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles, and enhancing the contraction of antagonist's muscles, thus avoiding postural asymmetry.
The GPR method includes eight therapeutic postures, lying, sitting or standing, to be held for 15/20 minutes each. Postures can be variously combined during sessions. Postures are chosen on the basis of some parameters, such as the amount of pain, load capacity and age of the patient, and muscle chains to be stretched. to increase the standardization of treatment, it will be proposed only 2 or 3 postures.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Condition: Central Neuropathic Pain; Multiple Sclerosis
MeSH terms: Multiple Sclerosis; Neuralgia; Sclerosis
Study type: Interventional
Phase: Phase 2

Summary: 
      The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses
      of AVP-923 capsules in the treatment of central neuropathic pain in participants with
      multiple sclerosis.
    

Detailed description: 
      The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses
      of AVP-923 (dextromethorphan [DM]/quinidine [Q]) capsules containing either 45 mg DM and 10
      mg Q (AVP-923-45) or 30 mg DM and 10 mg Q (AVP-923-30) or 20 mg DM and 10 mg Q (AVP-923-20)
      compared to placebo, for the treatment of central neuropathic pain in a population of
      participants with multiple sclerosis (MS) over a 12-week period. The MS participant
      population enrolled includes participants with relapsing-remitting multiple sclerosis (RRMS)
      and participants with secondary progressive multiple sclerosis (SPMS).
    

Intervention name(s): AVP-923-45; AVP-923-30; AVP-923-20; Placebo
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): AVP-923-45 (dextromethorphan 45 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.; AVP-923-30 (dextromethorphan 30 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.; AVP-923-20 (dextromethorphan 20 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.; Matching placebo capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
Other intervention name(s): Nuedexta
Intervention MeSH terms: Quinidine; Dextromethorphan
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
Condition: Schizophrenia
MeSH terms: Schizophrenia
Study type: Interventional
Phase: Phase 4

Summary: 
      The study will assess the use of paliperidone palmitate compared with oral antipsychotic
      treatment in delaying time to a protocol-defined treatment failure over 15 months, in
      patients diagnosed with schizophrenia who have been incarcerated.
    

Detailed description: 
      The primary objective of this study is to compare the efficacy of paliperidone palmitate with
      oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15
      months, in patients diagnosed with schizophrenia who have been incarcerated. Protocol-defined
      treatment failure is defined as arrest, psychiatric hospitalization, increase in psychiatric
      services to prevent imminent hospitalization, discontinuation of antipsychotic treatment due
      to inadequate efficacy, treatment supplementation with another antipsychotic due to
      inadequate efficacy, discontinuation of antipsychotic treatment due to safety or tolerability
      or completed suicide. Protocol was amended on March 15, 2011 to reflect changes in the
      inclusion/exclusion criteria as well as the study objectives. Patients will receive either
      paliperidone palmitate 78, 117, 156, or 234 mg monthly by injection for fifteen months OR
      oral aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and
      risperidone at doses selected by the study doctor.
    

Intervention name(s): paliperidone; risperidone; haloperidole; perphenazine; aripiprazole; quetiapine; paliperidone palmitate; olanzapine
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): flexible dosing as prescribed by the study doctor for 15 months; flexible dosing as prescribed by the study doctor for 15 months; flexible dosing as prescribed by the study doctor for 15 months; flexible dosing as prescribed by the study doctor for 15 months; flexible dosing as prescribed by the study doctor for 15 months; flexible dosing as prescribed by the study doctor for 15 months; 78, 117, 156, or 234 mg monthly injection for 15 months; flexible dosing as prescribed by the study doctor for 15 months
Intervention MeSH terms: Olanzapine; Risperidone; Aripiprazole; Quetiapine Fumarate; Paliperidone Palmitate; Perphenazine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: Schizophrenia; Risperidone; Risperdal; Paliperidone palmitate; Aripiprazole; Haloperidol; Olanzapine; Paliperidone; Perphenazine; Quetiapine
Dexmedetomidine for Sedation During Radiological Interventional Procedures
Condition: Procedural Sedation
Study type: Interventional
Phase: Phase 4

Summary: 
      Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing
      interventional radiological procedures and measuring its different outcome variables.
    


Intervention name(s): Dexmeditomedine
Intervention type(s): Drug
Other intervention name(s): Dexmedetomidine at 0.6 mcg/kg/hr then 0.2 to 1 mcg/kg/hr.
Intervention MeSH terms: Dexmedetomidine
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: dexmedetomedine; sedation; interventional radiology
Use of Motivational Interviewing to Increase Contraception Use Among Young Women
Condition: Unplanned Pregnancy
Study type: Interventional

Summary: 
      Study design: This is a 2-phase study. During the first phase, the investigators developed a
      contraceptive counseling intervention based on the principles of Motivational Interviewing,
      trained counselors, and conducted a small pilot study to develop skills and refine the
      intervention.

      The second phase is this feasibility randomized controlled trial (RCT) to compare outcomes
      between:

      Group 1 - Women randomized to a 20-40 minute contraceptive counseling session based on the
      principles of motivational interviewing, vs.

      Group 2 - Women receiving usual clinic care.

      Population: Women, aged 15-29 years, presenting to the University of Chicago family planning
      clinic for termination of an unintended pregnancy.

      Hypothesis: A larger proportion of women who are randomized to receive the MI counseling
      intervention will be using very effective contraception 3 months after the intervention.
    


Intervention name(s): Counseling Intervention
Intervention type(s): Behavioral
Intervention description(s): 20-40 minute contraceptive counseling session based on the principles of motivational interviewing
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Prevention
Keywords: Contraception; Counseling
Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss
Condition: Androgenetic Alopecia
MeSH terms: Alopecia; Alopecia Areata
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of this study is to compare the efficacy of 3% Minoxidil lotion and 3% Minoxidil
      with 0.1% Finasteride lotion for 6 months in male pattern hair loss.
    


Intervention name(s): 3%Minoxidil lotion; 3% Minoxidil with 0.1% Finasteride lotion
Intervention type(s): Drug; Drug
Intervention description(s): 3% Minoxidil lotion apply two times a day; 3% Minoxidil with 0.1% Finasteride lotion apply two times a day.
Intervention MeSH terms: Minoxidil; Finasteride
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: minoxidil; finasteride; topical; lotion; male pattern hair loss; androgenetic alopecia
Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In HIV Infected Subjects
Condition: HIV Infection
MeSH terms: HIV Infections
Study type: Interventional
Phase: Phase 1

Summary: 
      The purpose of the study is to look at the levels of the drug abacavir (ABC) in blood. Also,
      the study will look at the levels of carbovir triphosphate (CBV-TP), which is the active
      substance produced from ABC in the bodyâ s cells which helps prevent HIV from multiplying.
      CBV-TP will be measured in specific blood cells. The amount of ABC and CBV-TP will be looked
      at when subjects receive ABC as a 300mg dose twice a day and compared with the levels when
      they receive ABC as a 600mg dose once a day.
    


Intervention name(s): abacavir
Intervention type(s): Drug
Intervention MeSH terms: Abacavir
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Human Immunodeficiency Virus; HIV; Abacavir regime; ABC
Kinematics of Lower Limb, Pain and Function of the Women With Patellofemoral Pain Syndrome
Condition: Patellofemoral Pain Syndrome
MeSH terms: Patellofemoral Pain Syndrome; Syndrome; Somatoform Disorders
Study type: Interventional

Summary: 
      Assess pain, function, trunk and lower limbs kinematic during functional tasks after hip
      muscle strengthening versus hip muscle strengthening and sensory motor training in lower
      limbs.
    


Intervention name(s): Strength; Sensorimotor
Intervention type(s): Other; Other
Other intervention name(s): Hip abductors and lateral rotators and knee extensors strengthening; Sensorimotor, balancing exercises, motor coordination, proprioceptive stimuli.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine
Condition: Diphtheria; Tetanus; Pertussis; Hepatitis B; Haemophilus Influenzae Type B
MeSH terms: Hepatitis B; Whooping Cough; Tetanus; Diphtheria; Hepatitis
Study type: Interventional
Phase: Phase 4

Summary: 
      The purpose of this study is to evaluate the safety and immunogenicity of an indigenously
      developed liquid pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)
      combination vaccine in healthy Indian infants as a part of the routine immunization in
      accordance with the EPI schedule.
    


Intervention name(s): Shan5
Intervention type(s): Biological
Intervention description(s): Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: Vaccine; Prevention; Diphtheria; Tetanus; Pertussis; Hepatitis B; Haemophilus influenzae type b; Healthy infants
Prescription Medication Interactions
Condition: Opioid Use; Sedative Use
Study type: Interventional
Phase: Phase 1

Summary: 
      This study will examine the effects of doses of opioid/placebo and doses of sedative/placebo,
      alone and in combination. The primary outcomes are related to pharmacodynamic measures
      (subjective ratings of drug liking and other abuse-related effects; physiological outcomes)
      to determine the interaction effects of these compounds.
    


Intervention name(s): Opioid Agonist; Sedatives
Intervention type(s): Drug; Drug
Intervention description(s): Active opioid agonist or placebo, administered orally; Active sedative or placebo, administered orally
Intervention MeSH terms: Hypnotics and Sedatives
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Basic Science
Keywords: opioid; sedative; opiate
Trauma-informed Personalized Scripts (TIPS) for Relationship Abuse
Condition: Violence; Abuse
Study type: Interventional

Summary: 
      This pilot study will evaluate a computer-based intervention titled "Trauma-informed
      Personalized Scripts" (TIPS). The goal of this intervention is to improve patient-provider
      communication about sensitive topics such as intimate partner violence (IPV) and reproductive
      coercion (RC). The main aim of this study is to pilot test TIPS in family planning clinics
      using a randomized study design to compare the basic version of TIPS (a computer-based
      assessment with provider scripts only) to an enhanced TIPS containing a tailored brief
      intervention for patients along with provider scripts. The investigators plan to recruit 240
      female patients ages 16-29 for this study.
    


Intervention name(s): TIPS-Plus; TIPS-Basic
Intervention type(s): Behavioral; Behavioral
Intervention description(s): Patients receive brief psycho-educational messages on a tablet computer following completion of questionnaire about personal experiences of intimate partner violence (IPV), sexual assault (SA), and reproductive coercion (RC). These messages are tailored to each patient and are based on their responses to specific items. The messages serve as prompts to encourage the patient to continue the discussion about various topics (healthy relationships, birth control methods, harm reduction) with their provider during their clinic visit. Simultaneously, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.; Patients complete tablet questionnaire about personal experiences of IPV/SA/RC and based on responses, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: intimate partner violence; reproductive coercion; women's health; relationship abuse
Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD
Condition: Attention Deficit Hyperactivity Disorder; INSOMNIA
MeSH terms: Hyperkinesis; Attention Deficit Disorder with Hyperactivity
Study type: Interventional

Summary: 
      Methylphenidate may improve sleep in children with ADHD. By leaving Daytrana
      (methylphenidate) patch for a longer time then 9 hours, many children report short sleep
      latencies and better quality of sleep.
    

Detailed description: 
      Once the optimal dose of Daytrana that controlled the ADHD symptoms is established. The patch
      will be removed 1, 2, and 3 hours before bed time in a random fashion, at weekly intervals,
      and parents will keep a sleep diary.

      25 patients will be enrolled in order to obtain statistical significance.
    

Intervention name(s): Daytrana; Daytrana; Daytrana; Daytrana
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): Daytrana patch 10-30 mg administered once daily for 9hr; Daytrana 10-30 mg worn once daily for 10 hr wear; Daytrana 10-30 mg worn once daily for 11 hr; Daytrana 10-30 mg worn once daily for 12 hrs
Other intervention name(s): methylphenidate transdermal system; methylphenidate transdermal system; methylphenidate transdermal system
Intervention MeSH terms: Methylphenidate
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Single (Participant)
Primary purpose: Treatment
Keywords: daytrana; sleep latency; adhd rating scales; ADHD
Efficacy of Epidural Etanercept in the Treatment of Sciatica
Condition: Sciatica
MeSH terms: Sciatica
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      Tumor necrosis factor (TNF)-alpha has been strongly implicated as a major contributing factor
      for the development of radiculopathy. In animal studies, the application of TNF-alpha to
      nerve roots results in pain behavior indicative of radiculopathy. The use of TNF-alpha
      inhibitors (etanercept and infliximab) have been shown to prevent this pain behavior.
      Open-label studies in humans have shown both etanercept and infliximab provide excellent,
      long-term relief in patients with acute radiculopathy from herniated disc. However, a recent
      placebo-controlled study failed to demonstrate any significant difference from placebo. The
      investigators have already established the safety of neuraxial etanercept in a trial that has
      just been completed (not yet published). The objective of this study is to determine whether
      small doses of epidural etanercept, an anti-TNF-a medication, is an effective treatment for
      LBP caused by nerve root irritation (i.e., radiculopathy).
    

Detailed description: 
      As per the wishes of the Dept. of the Army and Walter Reed Army Medical Center Dept. of
      Clinical Investigation, patients will be randomized in a 3:1 ratio to receive 2
      transforaminal epidural etanercept or saline injections at 2-week intervals. Both patients
      and physicians will be blinded as to the injectate and treatment group. There will be 3 study
      groups. Group I will receive either 2 mg of etanercept or saline per injection. Group II will
      receive either 4 mg of etanercept or saline per injection. Group III will receive either 6 mg
      of etanercept or saline per injection. In each group there will be 8 patients: 6 who receive
      etanercept and 2 who receive saline. As per a previous study we just completed, etanercept
      doses will not be escalated until all 6 patients have completed their 1-month follow-up
      visits without any evidence of toxicity or complications.
    

Intervention name(s): epidural injection of etanercept; placebo (control procedure)
Intervention type(s): Drug; Drug
Intervention description(s): 2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg; Two injections of epidural saline 2 weeks apart
Intervention MeSH terms: Etanercept
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: sciatica; low back pain; epidural; tumor necrosis factor
A Study of LY2216684 and Theophylline in Healthy Subjects
Condition: Major Depressive Disorder
MeSH terms: Depressive Disorder; Depressive Disorder, Major
Study type: Interventional
Phase: Phase 1

Summary: 
      The primary objective of this study is to confirm that LY2216684 is not an inhibitor of
      cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate
      for the enzyme. Because LY2216684 has been observed to increase heart rate in some healthy
      participants, this study will also assess heart rate when coadministered with theophylline.
    


Intervention name(s): LY2216684; Theophylline
Intervention type(s): Drug; Drug
Intervention description(s): 18-mg LY2216684 oral dose; 200-mg theophylline oral dose
Intervention MeSH terms: Theophylline
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Brain Function and EEG
Condition: Healthy; Mood
Study type: Interventional
Phase: Early Phase 1

Summary: 
      In this project, we will examine effects of MA on reward function using electroencephalograms
      (EEG), which will complement our ongoing study with MA and fMRI. We will determine how MA
      alters reward-related neural activity and how this is related to its subjective rewarding
      effects. The effects of MA on reward function will be examined using both reward-task-related
      activation and resting state activity. We will examine the effects of MA on ratings of drug
      liking and euphoria, as well as on EEG measures sensitivity to reward. Healthy young adults
      will undergo three EEG sessions with placebo and MA (10 and 20 mg), while performing the
      Monetary Incentive Delay task and the Stop Task, as a measure of inhibition. We will examine
      correlations between the neural responses and subjective responses to MA.

      Our central hypotheses are 1) that MA will increase feelings of alertness and well-being, and
      2) that MA will increase neural responses to anticipation and receipt of reward, and 3) that
      the effects of MA on mood will be correlated with its effects on neural responses to reward.
    


Intervention name(s): Methamphetamine; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Participants will be given 20 mg of Methamphetamine.; Participants will be given a placebo capsule that will only contain lactose.
Intervention MeSH terms: Methamphetamine
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Basic Science